Successfully reported this slideshow.
We use your LinkedIn profile and activity data to personalize ads and to show you more relevant ads. You can change your ad preferences anytime.
OSCAR (Olmesartan and CalciumAntagonists Randomized Study)
OSCAR (Olmesartan and Calcium AntagonistsRandomized Study)H Ogawa (Kumamotom University, Japan)American College of Cardiol...
OSCAR: Results• BP was adequately controlled in both groups but significantly more important  reductions were seen with co...
OSCAR: Commentary*"The OSCAR study provides the first evidence showing that a standard dose ofARB plus CCB combination is ...
Become a member of http://www.theheart.org    Become a fan on Facebook: http://www.facebook.com/theheartorg          Follo...
Upcoming SlideShare
Loading in …5
×

OSCAR trial - Summary & Results

1,200 views

Published on

http://www.theheart.org/web_slides/1225165.do

A randomized study on Olmesartan and Calcium Antagonists Randomized (OSCAR) using high-dose of olmesartan or standard dose calcium-channel blocker (CCB) (amlodipine or azelnidipine) with patients with uncontrolled hypertension

Published in: Health & Medicine
  • Be the first to comment

OSCAR trial - Summary & Results

  1. 1. OSCAR (Olmesartan and CalciumAntagonists Randomized Study)
  2. 2. OSCAR (Olmesartan and Calcium AntagonistsRandomized Study)H Ogawa (Kumamotom University, Japan)American College of Cardiology 2011 Scientific Sessions• Population and treatment: 1164 high-risk elderly Japanese patients with uncontrolled hypertension (SBP >140 mm Hg, DBP >90 mm Hg) on standard-dose (20-mg/d) monotherapy with the ARB olmesartan and ≥1 of the following risk factors: Cerebrovascular disease, cardiac disease, vascular disease, or type 2 diabetes mellitus Randomized to high-dose olmesartan (40 mg per day) or standard dose calcium-channel blocker (CCB) (amlodipine or azelnidipine) with 20-mg/day olmesartan Adding other antihypertensive drugs (except ARBs, ACE inhibitors, and CCBs) was allowed if BP remained uncontrolled• Primary outcome: A composite of CV events* and all-cause death*Including cerebrovascular disease, CAD, HF, other atherosclerotic disease, diabetic complications, andthe deterioration of renal function
  3. 3. OSCAR: Results• BP was adequately controlled in both groups but significantly more important reductions were seen with combination therapy SBP 2.4 mm Hg lower (p=0.0315) DBP 1.7 mm Hg lower (p=0.0240)• Primary end point: No significant difference seen between the two treatment arms 48 events in the combination group compared with 58 in the high-dose-ARB group (HR1.21; p=0.1717)• Subgroup analysis Patients with preexisting CV disease appeared to benefit more from combination therapy: significantly more CV events and death with high-dose- ARB (HR=1.63; p=0.02610)
  4. 4. OSCAR: Commentary*"The OSCAR study provides the first evidence showing that a standard dose ofARB plus CCB combination is superior to high-dose ARB in reducing adverseevents in elderly hypertensive patients with cardiovascular disease." - Dr Hisao Ogawa"Extremely relevant with our aging population, where in the US alone 11 000 babyboomers are turning 65 every day." - Dr Sara J Sirna"We definitely need a new study to examine whether ARB [dose] doubling or ARBplus CCB is good for diabetic hypertensive patients." - Dr Toyoaki Murohara*All comments from OSCAR: Antihypertensive choice in elderly should be guided by underlyingdisease (http://www.theheart.org/article/1207871.do)
  5. 5. Become a member of http://www.theheart.org Become a fan on Facebook: http://www.facebook.com/theheartorg Follow us on Twitter: http://www.twitter.com/theheartorgtheheart.org is the leading online source of independent cardiology news.We are the top provider of news and opinions for over 100 000 physicians.

×